Moreover, phosphodiesterase-5 inhibitors (PDE5 inhibitors), muscarinic receptor antagonists, and vasopressin analogs may also have beneficial effects on the BPH-LUTS. Here, PDE5A is linked to benign prostatic hyperplasia.